European Commission granted orphan designation for Lundbeck's drug asedebart in the EU market.
3 reports, 1 independent
Updated Sep 11
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
European Commission granted orphan designation for Lundbeck's drug asedebart in the EU market.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Lundbeck
Danish pharmaceutical company
-
European Commission
executive branch of the European Union